A new analysis reveals that while new medicines can benefit millions of patients, public spending on them in England over two decades has led to significant trade-offs, suggesting that funds might be better allocated to other health services. The study indicates that the NHS's spending on new drugs has resulted in a net loss of about 1.25 million healthy life years, as funds diverted to new medicines could have supported more health services. Researchers advocate for a more holistic view of drug cost-effectiveness and transparency regarding the consequences of prioritizing new drugs. Teljes cikk (Euronews.com)